It is well accepted that major acute events in cardiovascular diseases are the consequences of the rupture of a vulnerable atherosclerotic plaque. The main issue for medical imaging is thus to diagnose vulnerable lesions before rupture and sudden vessel occlusion. The pathogenesis of atherosclerosis contains an important inflammatory component, which has been recognized as a key process in the malignant evolution of the disease. Magnetic Resonance Imaging (MRI) has recently evolved from a powerful non invasive morphological diagnostic technique to a more functional one, and is rapidly moving to molecular imaging thanks to the conception of new MRI contrast agents. Progress in molecular MRI of atherosclerosis is performed using animal models, where it is necessary to develop adequate methodology to enable in-vivo plaque imaging both in rabbits and mice. The next step is to synthesize an MR contrast agent targeted to inflammation in the plaque. For this, various targeting strategies are under evaluation. In our example, a gadolinium contrast agent was designed to target adhesion molecules highly expressed in active atherosclerotic plaques. Then, the arterial wall contrast enhancement was evaluated in vivo in ApoE-/-mice after the intravenous injection of the new macromolecular gadolinium agent, functionalized to target inflammation. To enable dual detection by MRI and fluorescence imaging, a fluorochrome was grafted on the gadolinium platform.
Introduction
It is well accepted that major acute events in cardiovascular diseases are the consequences of the rupture of a vulnerable atherosclerotic plaque. The main issue for diagnostic using imaging modalities is thus to diagnose vulnerable lesions before their rupture and its dramatic cascade of events, i.e. thrombus formation and sudden vessel occlusion. The pathogenesis of atherosclerosis contains an important inflammatory component, which has been recognized as a key process in the malignant evolution of the disease. It can be described by a series of specific cellular and molecular responses {Libby, 2002}. Functional parameters such as vessel wall transport between blood and artery wall also play an important role in early stages of atherosclerosis and appear to change progressively with the evolution of the disease {Wu, 2006; McEver, 1997}.
Magnetic Resonance Imaging has recently evolved from a powerful non invasive morphological diagnostic technique to a more functional one, and is rapidly moving to molecular imaging thanks to the conception of new MRI contrast agents {Winter, 2003; Jaffer, 2006}. The first clinical application of non specific MR contrast agents for plaque imaging has been for the delineation of the fibrous cap that is covering a lipid rich core in an advanced and dangerous atherosclerotic lesion {Stary, 1995; Yuan, 2002; Wasserman, 2002}. As a thin fibrous cap is an indicator of a vulnerable plaque, paramagnetic gadolinium MR contrast agent, diffusing from the blood stream into the fibrous cap, were found very helpful to examine its thickness. Iron oxide nanoparticles, the second family of MRI contrast agent, are also seen as very promising as they are taken up by phagocytic cells, which are very important actors in inflamed and active atherosclerotic plaques {Nighoghossian, 2005; Ruehm, 2001; Kooi, 2003}.
MRI of atherosclerosis in animal models
Advances in the understanding of this complex multifactorial disease and the development of new drugs and markers of atherosclerosis are mostly performed using genetically selected (the Watanabe rabbit) or genetically modified (the Apolipoprotein knock-out or ApoE-/-mouse) animal models. The ApoE-/-mouse is well known to develop atherosclerotic lesions that have similar characteristics, evolution and distribution to those found in humans {Coleman, 2006}. The reference to evaluate plaque in these animals is still histopathology (Figure 1) . Thus, to explore in-vivo by MRI the functional state of the atherosclerosis plaque and its risk, it is necessary to develop adequate methodology to enable plaque imaging in these animal models. The first prerequisite is to achieve the requested spatial resolution (Figure 1 ) in the minimum acquisition time. For mice imaging, the preferred spatial resolution is an isotropic voxel with dimensions of less than 100 µm (Figures 1 and 2 ). For the measurement of plaque volume, high spatial resolution could be achieved ex vivo after hours of MRI acquisition ( Figure 2a ). However, it is far more challenging to find the best compromise in vivo.
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In this context, blood pool MRI contrast agents are very useful ( Figure 2b ) as they remain in the blood circulation for a long time and are more efficient on MR signal compared to non specific gadolinium agent. Briefly, paramagnetic gadolinium agents modify the contrast on proton MRI by their effects on the relaxation rate of protons in their neighbourhood, the socalled relaxivity. Thus, an efficient gadolinium agent is the one with the higher in vivo relaxivity, i.e. accelerating the proton relaxation nearby. For better evaluation of an MR contrast agent, the choice of the parameters of the MR sequence is essential: for paramagnetic gadolinium agents, highly T1-weighted sequences are requested to view their effect as a bright signal on MR images (Figure 2b ).
In summary, for plaque imaging in the mouse aorta, one has to implement a robust high spatial resolution and high temporal resolution T1-weighted sequence and to inject intravenously a specific MR contrast agent to help characterization (Figure 2b 
Specific functional markers for dual optical-MRI detection
To evaluate the risk associated with an atherosclerotic plaque, the major issue is to obtain a comprehensive view of ongoing cellular and molecular processes ( Figure 3 ). It is envisioned that this could be achieved by molecular imaging techniques using dedicated markers, i.e. radioactive tracers, fluorescent probes, or specific magnetic resonance, X ray or ultrasound contrast agents. MRI contrast agents have very recently made a substantial progress in this field especially for cardiovascular applications, as evidenced by the number of original publications and reviews on the subject {Weinreb Thus, after an intravenous injection and an initial biodistribution in blood, the molecular imaging agent should be retained on the diseased vessel wall via a specific interaction and act differently compared to its non specific control agent (Figure 3 ). It has also to be detected by the imaging modality, in our case MRI. For that, the marker should bear both the specific chemical function to stick on the plaque, and the gadolinium or iron ions to modify the MRI contrast. As MRI has a very poor sensitivity, the agent has to be present at a detectable concentration, typically in the nano or even micromolar range. A high relaxivity contrast agent is generally preferred, but a fluorochrome can also be added to this complex structure to gain in sensitivity with detection by optical imaging (Figure 3 ).
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Functional optical-MRI markers of atherosclerosis
Canet-Soulas (Figures 3 and 4) . 
Figure 3: Targeting the vulnerable plaque with a bi-modal (optical-MRI) functionalized MR contrast agent. The non specific MR marker, i.e. gadolinium (Gd) or iron based contrast agent (Fe) will remain in the blood stream, whereas the targeted agent (as represented in the box) will bind to a specific receptor on the inflamed vessel wall via a ligand-receptor like interaction (ligand or specific chemical functions in blue). The optimal design combines high specificity for the vulnerable plaque (the target) and a high sensitivity (interpretable diagnostic images at low dose). By adding a fluorochrome (Fluo), it could be detected precisely at a low concentration using microscopic fluorescence imaging. Last but not least, the challenge is to choose the optimal cellular or molecular target, e.g. activated endothelial cells (ECs), smooth muscle cells (SMCs), macrophages, lipids, enzymes,…
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Functional optical-MRI markers of atherosclerosis Canet-Soulas The biomimetic agent was synthesized by grafting key chemical functions for the interaction between P-selectin and its main ligand, PSGL-1, on the backbone of the carboxymethyl dextran gadolinium. A special care was taken to preserve the high relaxivity of the original blood pool agent, P717. We showed that this agent was able to be detected by a strong bright and persistent signal in the plaque, as seen in Figure 4 . To improve the sensitivity and characterization, rhodamine was chemically added to enable fluorescent detection of the newly synthesized marker ( Figure 5 ). The fluorescence of the compound allows a co-localization on microscopic preparation with inflammatory receptors on immunohistochemistry. The dual detection ensures to validate the in vivo results by the ex vivo preparation ( Figure 5 ) with a co-localization and a complete characterization of lesions on histopathology. 
4.
Conclusion and perspectives
The strategy of a marker for multimodalities is favoured by many groups as it can benefit from each technique {Aikawa Optical methods offer a greater sensitivity and may be very helpful for quantification of sparse epitopes. Moreover, it has been extensively used for in vitro tissue characterization using microscopic tools and for molecular bioengineering. Future works aim at developing nanotechnologies for both therapeutic and diagnostic for local delivery of drugs and in vivo monitoring by molecular imaging {Lanza, 2002; Winter, 2006; McCarthy, 2006; Weissleder, 2006} . However, for atherosclerosis and treatment of the vulnerable plaque, an important concern is the animal model, as there is no model for plaque rupture. In the ApoE-/-mouse, the most widely used model in molecular biology, acute cardiovascular events, i.e. myocardial infarction or stroke, are not observed and on histopathology, rupture have been reported only in
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Functional optical-MRI markers of atherosclerosis Canet-Soulas the inominate artery ( Figure 2 ) and is a rare phenomenon. Thus, design of dual imaging nanotechnologies for atherosclerosis is a challenging task and has to be performed in close collaboration between chemist, bioengineer, biologist, pathologist, imaging physicist and cardiovascular physician.
